These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 30381062

  • 1. Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?
    Magro F, Coelho R, Peixoto A.
    Curr Med Chem; 2019; 26(2):248-258. PubMed ID: 30381062
    [Abstract] [Full Text] [Related]

  • 2. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S, Heap GA, Ahmad T, Kim H, Kwon T, Chowers Y.
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [Abstract] [Full Text] [Related]

  • 3. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L, Peyrin-Biroulet L.
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [Abstract] [Full Text] [Related]

  • 4. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J, Kudrin A.
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [Abstract] [Full Text] [Related]

  • 5. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N.
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
    Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.
    BioDrugs; 2017 Aug; 31(4):299-316. PubMed ID: 28612180
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.
    Isaacs JD, Cutolo M, Keystone EC, Park W, Braun J.
    J Intern Med; 2016 Jan; 279(1):41-59. PubMed ID: 26403380
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, Hoentjen F.
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [Abstract] [Full Text] [Related]

  • 14. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P, Fiorino G, Danese S.
    Curr Pharm Des; 2017 Nov; 23(44):6759-6769. PubMed ID: 29205114
    [Abstract] [Full Text] [Related]

  • 15. Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.
    Gecse KB, Lakatos PL.
    Drugs; 2016 Oct; 76(15):1413-1420. PubMed ID: 27638739
    [Abstract] [Full Text] [Related]

  • 16. Experience with Biosimilar Infliximab (Remsima®) in Norway.
    Jahnsen J, Kaasen Jørgensen K.
    Dig Dis; 2017 Oct; 35(1-2):83-90. PubMed ID: 28147374
    [Abstract] [Full Text] [Related]

  • 17. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
    Farkas K, Molnár T.
    Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994
    [Abstract] [Full Text] [Related]

  • 18. The nocebo effect challenges the non-medical infliximab switch in practice.
    Boone NW, Liu L, Romberg-Camps MJ, Duijsens L, Houwen C, van der Kuy PHM, Janknegt R, Peeters R, Landewé RBM, Winkens B, van Bodegraven AA.
    Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
    [Abstract] [Full Text] [Related]

  • 19. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
    Blair HA, Deeks ED.
    BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
    [Abstract] [Full Text] [Related]

  • 20. Comparative effectiveness of the biosimilar CT-P13.
    Yoo DH.
    J Comp Eff Res; 2017 Nov; 6(8):693-712. PubMed ID: 29172717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.